Amplification of the c-erb B-2 oncogene and prognosis of breast adenocarcinoma.
Fifty patients with typical infiltrating ductal adenocarcinoma of the breast were studied for amplification of the c-erb B-2 (neu/HER-2) oncogene within the tumor DNA. Amplification, ranging from 4 to greater than 50 copies per cell, was observed in 17 (34%) of the samples. The presence of c-erb B-2 gene amplification was not significantly correlated with patient survival, metastases, recurrence, or overall histologic grade. However, amplification was significantly associated with increased mitotic activity. Also, amplification of c-erb B-2 showed a significantly negative association with both progesterone and estrogen receptor presence. Progesterone receptor presence correlated significantly with survival.
Heintz
N H
NH
Department of Pathology, University of Vermont, College of Medicine, Burlington 05405.
Leslie
K O
KO
Rogers
L A
LA
Howard
P L
PL
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D004273:DNA, Neoplasm / Q000032:analysis*; D005260:Female; D005784:Gene Amplification; D006801:Humans; D008875:Middle Aged; D009693:Nucleic Acid Hybridization; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D018719:Erb-b2 Receptor Tyrosine Kinases
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D011518:Proto-Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases